# Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

> **NCT03951259** · PHASE2 · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 32 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** SM934
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03951259
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-24
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-19
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03951259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03951259, "Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03951259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*